Please assess the completion status of the following clinical trial:

Trial Title: Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) opioid use disorder, severe~* Currently in treatment with methadone or buprenorphine~Exclusion Criteria:~* Requiring level of care higher than outpatient treatment for alcohol, sedative/hypnotics, or stimulants~* Any current mood episode requiring level of care higher than outpatient treatment~* History of psychotic disorder or bipolar disorder~* Currently pregnant~* Hepatic liver enzymes greater than 3x upper normal limit~* Hypersensitivity to cannabinoids or sesame oil (cannabidiol solution comes in sesame oil emulsion)~* Currently taking any medications with known significant pharmacokinetic interactions with CBD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cannabidiol (Type: EXPERIMENTAL): As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically 600mg of oral cannabidiol once daily for 3 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).